Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии on Психиатрия и психореаниматология

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Fri, 03 Feb 2012 13:25:21 +0400

кстати, о кетамине и депрессии.
что не находилась на пабмеде, есть в евровики:

Antidepressant use When treating patients suffering from complex regional pain syndrome (CRPS) with a low-dose (subanesthetic) ketamine infusion, it was observed that some patients made a significant recovery from associated depression . This recovery was not formally documented, as the primary concern was pain management. It was not possible to quantify to what degree depression recovery was secondary to the patient’s recovery from CRPS. One trial administered a short-term ketamine regimen to patients with severe depression, with the dose carefully monitored to prevent hallucinogenic side effects. The patients’ normal medications were continued as it was feared that stopping them might result in severe depressive episodes. Before and following each treatment with ketamine, at patient clinic visits, the Beck Depression Inventory (BDI) and the Hamilton Rating Scale for Depression (HAMD-17) were obtained. Two of the patients demonstrated significant, long-term improvement. [ 71 ] Another small study found that ketamine significantly improved treatment-resistant major depression within hours of injection. [ 72 ] The improvement lasted up to one week after the single dose. [ 73 ] These patients were previously treatment resistant, having tried an average of six other treatments that failed.The researchers apparently attribute the effect to ketamine being an NMDA receptor antagonist . [ 74 ] Those findings of Zarate et al. corroborate earlier findings by Berman et al. . [ 75 ] However Zarate et al. do raise some concerns about their results due to a possible lack of blinding, because of the inebriating effects of low dose ketamine infusion, and it is recommended that future studies include an active placebo .

These findings are corroborated by Liebrenz et al., who successfully, according to an attending doctor, treated a patient with a treatment-resistant major depression and a co-occurring alcohol and benzodiazepine dependence by giving an intravenous infusion of 0.5 mg/kg ketamine over a period of 50 minutes and Goforth et al. who helped a patient with severe, recurrent major depressive disorder that demonstrated marked improvement within 8 hours of receiving a preoperative dose of ketamine and one treatment of electroconvulsive therapy with bitemporal electrode placement. [ 76 ] [ 77 ]

However, a new study in mice by Zarate et al. shows that blocking the NMDA receptor is an intermediate step. According to this study, blocking NMDA increases the activity of another receptor, AMPA , and this boost in AMPA activity is crucial for ketamine’s rapid antidepressant actions. NMDA and AMPA are receptors for the neurotransmitter glutamate . The glutamate system has been implicated in depression recently. This is a departure from previous thinking, which had focused on serotonin and norepinephrine . The glutamate system may represent a new avenue for treatment and research. [ 78 ]

Krystal et al. retrospectively compared the seizure duration, ictal EEG, and cognitive side effects of ketamine and methohexital anesthesia with ECT in 36 patients. [ 79 ] Ketamine was well tolerated and prolonged seizure duration overall, but particularly in those who had a seizure duration shorter than 25 seconds with methohexital at the maximum available stimulus intensity. Ketamine also increased midictal EEG slow-wave amplitude. Thus, a switch to ketamine may be useful when it is difficult to elicit a robust seizure. Faster post-treatment reorientation with ketamine may suggest a lower level of associated cognitive side effects.

Kudoh et al. investigated whether ketamine is suitable for depressed patients who had undergone orthopedic surgery. [ 80 ] Depressed mood, suicidal tendencies, somatic anxiety, and hypochondriasis significantly decreased in the active group as compared with the control. The group receiving ketamine also had significantly lower postoperative pain.

Acute administration of ketamine at the higher dose, but not imipramine , increased BDNF protein levels in the rat hippocampus . The increase of hippocampal BDNF protein levels induced by ketamine might be necessary to produce a rapid onset of antidepressant action in rats.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Sat, 14 Jan 2012 02:05:18 +0400

многие психиатры из этих ссылок говорят медленно, не понятно почему.

Заразились от пациентов.
Про борнавирус и антивоспалительную терапию, как всегда на закуску и без практического применения.
У шизофреников бывает как избыточное метилирование, так и недометилирование, которое гораздо тяжелее “закручивания хвостов”.
Исходное интервью - дурное, если такие неначитанные профессора учат, то понятно какие психиатры получаются.
Кризис - есть, но выходить из него не хотят, психиатрам так лучше, кризис - он для больных и родственников.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 22:38:13 +0400

Я помню где-то видел сравнение действия кетамина СИОЗС. Они там даже что-то общее нашли, вроде какой-то адренорецептор который реагирует и на то и на другое схожим образом.

Вообще NMDAr самый изучаемый благодаря его уникальной функции в ЦНС. Реально только два заболевания прямо непосредственно связанны со степенью его активности это шизофрения и эпилепсия. Блокада вызывает кататано-онейроидный психоз, чрезмерная активация судорожный припадок, все. А вообще исследований о том на сколько он активен когда на дворе март месяц тьма. Если откроете неврологию, любую, реально пох, абсолютно любую, будь-то ЧМТ, инсульт, Альцгеймер или олигофрения - тонны информации.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 21:58:29 +0400

норм исследований по NMDA при быстром поиске не попалось, за потенциально интересные статьи просят деньги:
NMDA for depression
predictors of clinical improvement to ketamine in depression

короче, если очень хочется, сам экпериментально устанавливаешь оптимальную дозу кетамина и вперед.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 21:47:37 +0400

нЕкогда наткуналась на шикарнейший материальчик (cross, вам должно понравиться) о воспалительных процессах при депрессии.
[длинновато, сложновато, но изучить советую]

Abstract
Multiple lines of evidence suggest that inflammation and glutamate dysfunction contribute to the pathophysiology of depression. In this review we provide an overview of how these two systems may interact. Excess levels of inflammatory mediators occur in a subgroup of depressed patients. Studies of acute experimental activation of the immune system with endotoxin and of chronic activation during interferon-α treatment show that inflammation can cause depression. Peripheral inflammation leads to microglial activation which could interfere with excitatory amino acid metabolism leading to inappropriate glutamate receptor activation. Loss of astroglia, a feature of depression, upsets the balance of anti- and pro-inflammatory mediators and further impairs the removal of excitatory amino acids. Microglia activated by excess inflammation, astroglial loss, and inappropriate glutamate receptor activation ultimately disrupt the delicate balance of neuroprotective versus neurotoxic effects in the brain, potentially leading to depression.
Introduction
Depression is a common and debilitating disorder for which current treatments are inadequate. The pathogenesis of depression is not well understood. The annual prevalence of depression is 7% and the lifetime prevalence is 16%.1,2 In addition to significant disability,3 depression is associated with excess mortality,4,5 particularly from cardiovascular disease.6 Current antidepressants, which target monoamines, only produce remission in 30% of patients. Part of the problem lies in the fact that the pathophysiology of depression has not been elucidated, and treatments are based on empirical data, not mechanisms of action. It remains unclear how these drugs actually work, since their ability to increase synaptic concentrations of monoamines is immediate, while their clinical effects take 2–4 weeks to become apparent.7 The aim of this article is to provide an overview of studies implicating inflammation in depression, and propose a model of how excess inflammation may interact with glutamate and glia to cause depression.

For this review, we searched PubMed with the following combinations of keywords: “depression AND inflammat*”, “depression AND cytokines”, “depression AND glutamate”, “depression AND glia”, “cytokines AND glutamate”, and “inflammat* AND glutamate.” Abstracts were read and articles chosen based on content. Articles addressing the role of inflammatory mediators in depression were selected. In addition, we included all articles addressing interactions between glutamate and inflammation, and between depression and glia.
Inflammation in Depression
Immunologic alterations in depression have been described for over 2 decades8 and the current hypothesis is that excess inflammation plays a role.9,10 The innate immune system can favor a T helper cell type 1 (Th1) or a Th2 response. During a Th1 response activated macrophages secrete so-called pro-inflammatory mediators, such as interferon-γ (IFN-γ), tumor necrosis factor (TNF), and interleukin-1 (IL-1) and IL-2. A Th2 response is characterized by antibody production and anti-inflammatory mediators, IL-4, IL-5, and IL-10, which inhibit the Th1 response. This balance is essential to prevent excess inflammation which can have deleterious consequences. It has been repeatedly shown that a subgroup of patients with depression has elevated plasma levels of pro-inflammatory mediators, including IL-1, IL-2, IL-6, TNF, and C-reactive protein.8,11-14 In patients with depression the ratio of IFN-γ to IL-4 was elevated, and this ratio decreased with antidepressant treatment.15 Multiple studies14,16-18 have shown that there is a decrease in Th1 mediator levels with antidepressant treatment, indicating that one potential mechanism of action of antidepressant treatments is decreased inflammation. Researchers19 have found that higher levels of TNF at baseline may predict a poor response to escitalopram. In a rare prospective study,20 an increased inflammatory state at baseline (elevated levels of C-reactive protein and increased capacity of leukocytes to produce IL-1) predicted later onset of depression in elderly individuals without a prior history of depression, suggesting that excess inflammation precedes depression. In summary, inflammatory mediator levels are elevated in depression, the Th1:Th2 balance is off, and such excess inflammation may play a role in the development of depression and contribute to poor response to antidepressants.

It is important to keep in mind that the peripheral and central inflammatory systems operate in parallel. In rodents, peripheral inflammatory stimuli induce expression of inflammatory mediators in the brain.9 Conversely, over-expression of IL-1 in the rodent brain led to increased peripheral production of inflammatory mediators,21 highlighting this bi-directional communication between central and peripheral inflammatory systems. In monkeys, intravenous administration of IL-1 led to increases in IL-6 in cerebrospinal fluid (CSF),22 and in hepatitis C patients receiving IFN-α treatment, CSF levels of IL-6 increased during treatment (A. Miller, MD, et al, written communication, 2007), demonstrating that, as seen in rodents, peripherally activating the immune system activates inflammatory pathways in the primate brain. Consistent with this, in patients with depression levels of IL-1 in CSF are also elevated,23 suggesting that, in depression, there is excess inflammation both centrally and peripherally. Because an appropriate Th1:Th2 balance is of crucial importance to avoid the deleterious effects of excess inflammation, several redundant mechanisms regulate this balance. For example, a recent study24 demonstrated that repeated endotoxin stimulation of monocytes induced chromatin modifications which silenced the transcription of inflammatory genes, while priming the transcription of antimicrobial genes. It is possible this or other regulatory mechanisms are deficient in depression, leading to excessive inflammation.

In patients with hepatitis C treated with IFN-α up to 45% develop depression.25 IFN-α-induced depression is associated with increases in plasma levels of IL-6 and TNF,26 inflammatory mediators commonly elevated in depression. As previously described, IL-6 levels also increase in CSF. On functional magnetic resonance imaging, IFN-α treatment is associated with hypometabolism in prefrontal and temporal regions, findings similar to those in depression27,28 demonstrating that peripherally administered IFN-α affects brain regions implicated in depression. Endotoxin, a cell-wall component of gram-negative bacteria, is a potent stimulus of the innate immune system. In rodents, administration of endotoxin leads to a constellation of behaviors, including decreased sucrose preference (akin to human anhedonia, a core symptom of depression), reduced exploratory and social behaviors, reduced food intake, and increased sleep.9 In humans, endotoxin at doses from 2–4 ng/kg causes influenza-like symptoms, such as fever, chills, headache, and myalgias.29,30 Lower doses of endotoxin (0.8 ng/kg) are insufficient to cause sickness symptoms, but do cause depressive symptoms.31 Another non-sickness-inducing inflammatory stimulus, Salmonella typhi vaccine, also induces negative mood.32

Inflammatory stimuli can induce psychiatric symptoms that are not dependent on the physical discomfort associated with inflammation and do not require a full-blown sickness syndrome.
Anti-inflammatory Agents Have Antidepressant Effects
If depression is associated with excess inflammation, one would expect that inhibiting inflammation would reduce depressive symptoms. Eicosanoids are inflammatory mediators that mediate fever, vascular permeability, and neutrophil chemotaxis. The enzyme that converts arachidonic acid to eicosanoids is called cyclooxygenase-2, and inhibition of this enzyme reduces inflammation. In a randomized, placebo-controlled trial of the cyclooxygenase-2 inhibitor celecoxib in depressed patients treated with reboxetine,33 celecoxib augmentation was more efficacious than placebo. Another anti-inflammatory medication used in various forms of arthritis is etanercept, an antagonist of the inflammatory mediator TNF. In a trial in patients with psoriasis,34 it was demonstrated that etanercept reduced depressive symptoms independent of improvement in psoriatic symptoms, such as skin involvement and joint pain. This study suggests that blocking TNF can treat depressive symptoms, which is consistent with elevations in TNF plasma levels seen in depression, the fact that such levels go down with treatment, and the fact that knocking-out TNF receptors in mice reduces depressive-like behaviors.34

Medical Comorbidities
Disorders associated with excess inflammation or other immune abnormalities, including diabetes, coronary artery disease, Crohn’s disease, rheumatoid arthritis, cancers, human immunodeficiency virus, and multiple sclerosis36,37 are associated with an increased prevalence of depression. For example, after myocardial infarction (MI), 20% to 30% of patients develop depressive symptoms.6 Interestingly, symptoms of post-MI depression differ from classic depression, as post-MI depression is characterized by prominent fatigue, and irritable rather than depressed mood.38 Fatigue and irritability are also common symptoms in IFN-α-induced depression.25,39 In cancer survivors, fatigue is associated with inflammatory mediators.40 Thus, it is possible that fatigue in post-MI depression and in other medical disorder, and during IFN-α treatment, is caused by excess inflammation. Consistent with this, neurovegetative symptoms of depression, including fatigue and disturbances of sleep and appetite, predict development of atherosclerosis.41 Because depression is a heterogeneous syndrome, it is necessary to study the associations between inflammation and specific symptoms, such as fatigue, sleep, and appetite, rather than depression as a categorical construct. Whether fatigue or other neurovegetative symptoms occur more frequently in depressed patients with elevated inflammatory mediator levels is a question that has not been answered. Fatigue, and its neurobiological sibling anhedonia, often do not improve with current treatments, such as selective serotonin reuptake inhibitors,42 and this could be because inflammation-related depressive symptoms are more resistant to monoaminocentric treatments. Capuron and colleagues43 showed that increased activity in basal ganglia, specifically the left nucleus accumbens and putamen, correlated with IFN-α-induced fatigue, pointing to a potential neuroanatomical substrate of inflammation-induced fatigue. In the future, such studies may identify brain regions that mediate each specific symptom of depression.

Mechanisms Through Which Inflammation Could Cause Depression
We have reviewed how depression is associated with increased peripheral inflammation, how inflammatory states can cause depressive symptoms, and how reducing inflammation can alleviate depressive symptoms. We will now review some mechanisms through which inflammation could produce depression, including interference with serotonin (5-HT) synthesis, glutamate metabolism, glial cell function, and neuroplasticity.

Inflammation, Serotonin, and Kynurenine
The amino acid tryptophan is the precursor of 5-HT and melatonin. The enzyme indoleamine 2,3-dioxygenase (IDO) converts tryptophan to kynurenine (Figure 1). When tryptophan is shuttled down the kynurenine pathway there is less tryptophan available to make 5-HT. This is akin to tryptophan depletion, an experimental paradigm used to induce depressive symptoms in susceptible individuals.44 In microglia and macrophages, IDO expression is induced by Th1 cytokines, such as IFN-γ, IL-1, and TNF, and inhibited by Th2 cytokines, such as IL-4 and IL-10.45 Thus, excess inflammation may reduce 5-HT levels through activation of this pathway in central and peripheral macrophages, contributing to depression.
In IFN-α-induced depression, plasma levels of kynurenine increase, however, paroxetine reduced depressive symptoms without decreasing kynurenine levels,46 suggesting that increased synaptic 5-HT caused by paroxetine can compensate for the tryptophan siphoned off to the kynurenine pathway.

Recently, it was shown that IFN treatment in hepatitis patients increased CSF levels of IL-6 and decreased levels of 5-hydroxyindoleacetic acid, a 5-HT metabolite. Depressive symptoms correlated with decreases in 5-hydroxyindoleacetic acid, suggesting that the depressogenic effects of IFN-α may involve the kynurenine pathway (A. Miller, MD, et al, written communication, 2007).

Inflammation and Glutamate
Over the last few years, evidence suggests that glutamate plays a role in depression.47,48 Patients with depression, both during an acute episode and during remission, have elevated levels of glutamate in some brain regions.49,50 The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine produces a profound antidepressant effect with almost immediate onset,51,52 and recent data53,54 on antidepressant properties of the glutamate modulator riluzole are promising. The current hypothesis47 holds that excessive glutamate action, especially extrasynaptic glutamate, may be deleterious for neuronal function and contribute to depression.

Inflammatory mediators can, through activation of the kynurenine pathway (Figure 1), increase glutamate receptor agonism. The two main end-products of the kynurenine pathway bind to NMDA receptors: Kynurenic acid is an NMDA receptor antagonist, while quinolinic acid is an NMDA receptor agonist. Although IDO, the rate-limiting enzyme in the kynurenine pathway, is expressed in multiple cell types, microglia are the only cells in the central nervous system that express the complete enzymatic pathway required for the synthesis of quinolinic acid.55 Therefore, inflammatory mediators acting on microglia will increase the quinolinic acid to kynurenic acid ratio, leading to net NMDA agonism.15,56 In addition to NMDA agonist action, quinolinic acid directly causes release of glutamate.57 Thus, inflammatory mediators can cause an environment of excess glutamate receptor agonism and resultant neurotoxicity. Although glutamate can cause neurotoxicity, it is important to point out that neurotoxicity in depression has not been unequivocally demonstrated.

Interactions between inflammatory mediators and glutamate are bi-directional. Glutamate causes TNF release from endotoxin-activated microglia.58 The NMDA antagonist ketamine inhibits endotoxin-induced TNF production in glia,59 and memantine, another NMDA receptor antagonist, decreased endotoxin-induced activation of microglia.60 Thus, on one hand, inflammatory mediators can cause an environment of excess glutamate receptor agonism through increased quinolinic acid production and glutamate release. On the other hand, activation of NMDA receptors, by glutamate or quinolinic acid, may activate microglia and cause further release of inflammatory mediators, causing a vicious circle (Figure 2). Astrocytes are responsible for taking up excess glutamate to protect neurons from toxicity. This occurs through excitatory amino acid transporters (EAAT).61,62 Knockdown of glial transporters (EAAT1 or EAAT2) leads to glutamate excitotoxicity, while knockdown of the neuronal transporter does not.63,64 In cortical lesions in multiple sclerosis, the presence of activated microglia correlated with focal loss of EAAT1/2, while no loss was seen in the absence of activated microglia.65 This indicates that inflammatory mediators released by microglia adversely affect astroglial expression of EAAT and, thus, could impair glutamate removal.
Inflammatory mediators can cause excess glutamate receptor agonism through three different mechanisms, including increased production of quinolinic acid, increased release of glutamate, and inhibition of excitatory amino acid removal by astroglia.

Inflammation, Microglia, and Neuroplasticity
Studies in animals and humans indicate that neurotoxicity and loss of neuroplasticity play a role in depression.66-68 Inflammatory mediators can activate microglia that release neurotoxic substances,69 but microglia can also have neurotrophic effects.70,71 For example, microglia produce the IL-1 receptor antagonist (IL-1ra) which protects neurons from the harmful effects of IL-1.72 In patients who suffered traumatic brain injury, high IL-1ra levels and high IL-1ra:IL-1 ratios in brain microdialysates predicted better outcomes,73 demonstrating the clinical importance of keeping inflammation under control. The Th2 mediator IL-4 induces a neuroprotective microglial phenotype, whereas activation with endotoxin or the Th1 mediator IFN-γ leads to neurotoxic microglia.71 Thus, an inappropriate Th1:Th2 balance, as found in some patients with depression, could impair neuroplasticity by shifting the microglial phenotype toward a neurotoxic one.

Once stimulated by inflammatory signals, microglia stay activated for several months and continue expressing inflammatory mediators, including IL-1 and TNF.69,74,75 Mice lacking the enzyme required to synthesize IL-1 have reduced sickness behavior and lower expression of neurotoxic and inflammatory mediator genes in the brain after peripheral endotoxin injection.76 On the other hand, genetic overexpression of IL-1 in the brain led to reduced spontaneous behavior, axonal injury, and increased peripheral expression of inflammatory mediators.21 Of note, blockade of the enzyme required for IL-1 synthesis inhibits glutamate neurotoxicity and activation of microglia,77 suggesting that glutamate neurotoxicity requires IL-1 and illustrating the reciprocal and complex interactions among inflammatory mediators, glutamate, and microglia.

A recent study78 found that when rats were given IFN-α for 9 weeks degeneration of 5-HT and noradrenergic axons occurred, indicating that neurotoxicity induced by inflammation can specifically target monoaminergic systems involved in depression. This is fascinating given the prevalence of emergent depression during IFN-α treatment. Antidepressants have been shown to inhibit IFN-γ-induced microglial production of IL-6 and nitric oxide,79 suggesting that inhibition of brain inflammation may be one mechanism of action of antidepressants. As occurs in peripheral macrophages,80,81 microglia express brain-derived neurotrophic factor and its receptor, tyrosine receptor kinase B.82 Brain-derived neurotrophic factor is believed to play an important role in depression,83 and any alteration of microglial production of this or similar growth factors could thus contribute to the occurrence of depression. Figure 3 illustrates the variety of mechanisms through which inappropriate microglial activity could cause depression through deleterious effects on neuroplasticity.

Inflammation, Astroglia, and Neuroplasticity
Astroglia also play a role in neuroplasticity through secretion of neurotrophic factors, and the number of astroglia is reduced in depression.84 When astroglia were added to neurons in culture, there was an increase in the number of mature synapses,85 whereas removal of astroglia caused a decrease in the number of synapses.86 As previously mentioned, inflammatory mediators induce microglial production of quinolinic acid, which, like glutamate, can be neurotoxic.87-89 Astrocytes are responsible for removing excess glutamate to protect neurons from toxicity. Down-regulation of astrocytic EAAT in amyotrophic lateral sclerosis may play a role in disease progression.90 Interestingly, riluzole, a medication used in amyotrophic lateral sclerosis and that has shown preliminary efficacy in depression,53,54 enhances glutamate uptake by astroglia.91 This may occur through upregulation of astrocytic EAAT expression (G. Sanacora, MD, PhD, unpublished study, 2007). Thus, the antidepressant effects of riluzole may reside in its ability to enhance glutamate uptake in astroglia, possibly compensating for a loss of astroglia and counteracting inhibition of astroglial EAAT expression by activated microglia.

Studies have shown that in patients with depression there is a decrease in glial fibrillary acidic protein staining, indicating a loss of astrocytes.92,93 A reduction in the number of astroglia would impair the brain’s capacity to recycle neurotoxic excitatory amino acids and decrease the availability of neurotrophic factors. As microglia preferentially synthesize Th1 mediators and astrocytes preferentially secrete Th2 mediators, the balance between microglial and astrocyte activity may be of pivotal importance for optimal brain function. Reduced numbers of astrocytes would impair the Th2 anti-inflammatory effects that inhibit microglial Th1 responses, facilitating a neurotoxic microglial phenotype. This, combined with reduced amounts of astroglia-derived neurotrophic factors and increased excitatory amino acid toxicity, would cause neuronal damage and impaired neuroplasticity (Figure 3). Treatments for depression, such as antidepressants and electroconvulsive therapy, has been shown to increase levels of glial markers and neurotrophic factors produced by glial cells.67 Thus, astrocytes and microglia are promising targets in the development of new treatments for depression.
Discussion
Although elevation in plasma levels of inflammatory cytokines in depression has been repeatedly shown, some studies have failed to replicate this finding. One reason is that depression is a heterogeneous disorder and excess inflammation only occurs in a subpopulation of depressed patients. Plasma levels of inflammatory mediators are influenced by genetic polymorphisms.94 Although beyond the scope of this review, the genetic background will thus determine what level of inflammation will occur after a specific pathogen exposure and also to what extent this has detrimental effects, such as causing depression.95 Although chronic inflammation may be associated with the development of depression and other disorders, chronic inflammation may have provided a survival benefit in terms of fighting off pathogens in an era before antibiotics.10 Genes that predispose one to chronic inflammation—and perhaps to depression—may thus have been conserved because of their survival benefit. We have seen how abundant evidence supports a link between inflammation and depression. The mechanisms whereby inflammation leads to depression proposed here incorporate current monoaminergic, glutamatergic, and neurotrophic hypotheses rather than demanding an entirely new framework. The interactions between inflammatory systems, on one hand, and 5-HT, glutamate, and neurotrophic systems on the other hand help explain the associations between depression and inflammation. The bi-directional interactions between peripheral and central inflammatory pathways raises the possibility that inflammatory dysfunction in the brain in depression contribute to the peripheral inflammation. This is important for diseases associated with depression, such as cardiovascular disease, in which inflammation may play a pivotal role. Thus, a re-examination of depression and its pathophysiology through the lens of inflammation may lead to a more complete understanding of the disorder and improved ways to treat it.

Conclusion
Immunologic abnormalities, especially indices of excess inflammation, are a common finding in patients with depression. Although the causal direction of these associations are unclear, there is increasing evidence suggesting that inflammation could, in a subgroup of patients and in some medical conditions, contribute to the pathogenesis of depression. This may occur through interference with monoaminergic, glutamatergic, and neurotrophic systems.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 20:09:58 +0400

eternityname пишет:
ибо дальше серотониновой теорией еще не ушли

Дык, все приехали. Дефицит серотонина являеться объективным доказанным фактором патогенеза депрессии. Куда дальше развиваться - в ультра мега высокую селективность, двигаться в один, два рецептора. Вообще все будущие психофармакологии в такой ультраселективности.

про глутаматовую у шизофрении знаю, про депрессии не в курсе.

Вот тут есть че сказать. Никто даже не планируют прямо воздействовать на глутаматный сайт NMDAr из-за “возможного” вреда мозгу. При чем ни в одном(!!!) эксперименте in vivo такой вред не доказан, только in virto и в теории. А такое воздействие является наиболее эффективным лучше всего выводящие разных бабунов из РСР-шного трипа, со слов тех кто эти трипы исследует.
Тут требования внатуре очень завышенные.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 17:11:34 +0400

Anima, спасибо! Интересная статья.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 12:35:38 +0400

У SSRI побочки ахтунг по современным меркам. Сексуальные нарушения, анарексогенность, безволие. Далеко не пустышка.

Тогда еще более странен вопрос, зачем жрут-то тогда? И там контекст был к подходу о разработке, что, мол, жалуются что требование высокие, просто логично - что любой новый класс препаратов будет иметь явные специфические проблемы, смазывающие красивую картинку, так на самом деле у любого препарата, но некоторые это возводят в “истерию”, всего-то. Но кризис есть, конечно, ибо дальше серотониновой теорией еще не ушли, но мне кажется, что если что-то и изобретут реально новое, то у него явно с побочками будет тоже не подарок, ибо вмешиваться придется еще в более глубокие функции, а может уже и придумали что-нибудь новое в теории о депрессиях, про глутаматовую у шизофрении знаю, про депрессии не в курсе. В любом случае все относительно, чаще всего такие вот скачки только и идут рывками, но говорить о кризисе глупо.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 12:06:37 +0400

eternityname пишет:
Зачем изобретать новые антидепрессанты, если основные препараты и так жрут и радуются?

У SSRI побочки ахтунг по современным меркам. Сексуальные нарушения, анарексогенность, безволие. Далеко не пустышка.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 10:34:55 +0400

Посмотрел первую статью, откуда такая чудовищная цифра-то? Хотя я так понял, что в Европе уже излюбили выписывать антидепрессанты по каждому чиху, а толку-то? Насколько я помню эффективность в большей группе легких невротиков чуть более, чем нулевая, что вообще ставит под сомнение диагноз. Кризис в психиатрии - не в том, что не могут, а в том, что не хотят. Зачем изобретать новые антидепрессанты, если основные препараты и так жрут и радуются? Гипердиагностика же выгодна самим компаниям, чем лучше статистика и количество больных, ведущихся на препараты - тем меньше надо разрабатывать новое. Поэтому, как мне кажется, проблема не в психиатрии как науки, но в психиатрах которые эту науку гробят своей гипердиагностикой и которым оно собственно и не надо. Почему-то нейролептикам тяжелые побочки не мешают, а антидепрессанты обязательно должны быть “пустышками” из-за идиотов, породившую такую систему, что спрос на антидепрессанты диктуют не больные, а наивные люди, использующие таблетки как плацебо, которым понятное дело побочки и не нужны. Ради них же все, а не больных! Угу, и вина тут психиатров, а не науки, печально это…

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 04:14:19 +0400

Anima пишет:
Не случайно, что за последние 10 лет в Европе лицензирован лишь один агомелатин (Вальдоксан®, Servier).

Это 10 лет уже кризис? Какой-то лохутный топик.
Статистика SCHResearch крайне иная. По шизе 90 исследований в неделю, с 24 за 20 лет. Кризис есть, но он не кризис финансирования.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 04:05:58 +0400

Эта лекция - джинса абилифая.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 01:32:05 +0400

Послушала лекцию Незнанова “Проблема приверженности пациентов шизофренией к лечению”
Название какое-то нелепое. Что значит приверженность?
“Совок - приверженец лечения себя сероквелем”. Бред какой-то.
Очевидно, калька с английского:
adherence to - приверженность, верность, строгое соблюдение.

Некоторые картинки в презентации понравились (см. странный график внизу). Но говорит Незнанов страшно медленно (скорость речи намного ниже среднего).
Я очень тяжело воспринимаю медленную речь, почти всегда прогуливала лекции таких преподов, пожалела его студентов.

Кстати, многие психиатры из этих ссылок говорят медленно, не понятно почему.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 00:21:44 +0400

Спасибо.
Много интересных лекций
Например, эта
Quo Vadis? (Куда идешь?). Тот же Морозов.
Зато

Сегодня по “Эху Москвы” ведущая назвала психиатрическую больницу “дурдомом”.
Покоробило

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Thu, 12 Jan 2012 00:14:10 +0400

Ну гугл, как и сами психиатры. полагает, что это http://www.psychiatr.ru/

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Wed, 11 Jan 2012 23:59:19 +0400

А это для Кросса:

По свидетельству бывшего президента Всемирной психиатрической ассоциации (ВПА) M. Maj, «пациенты с психозами и пограничными расстройствами лечатся в общесоматической сети (или не лечатся, или занимаются самолечением), но ни разу не были направлены и не осмотрены психиатром».

Главная опасность клинической психиатрии – психологизация

Очевидно, что наши научные усилия будут тщетными без заботы о подготовке кадров. И в этом смысле необходимо использовать все возможности Российского общества психиатров по совершенствованию последипломного образования. Прежде всего, необходимо разработать систему непрерывного медицинского образования для психиатров с правилами начисления накопительных кредитов. Уже фактически создан свой собственный интернет-ресурс РОП для непрерывного медицинского образования, который будет не только содержать достоверную и современную информацию, но и иметь бесплатный доступ для абсолютно всех членов РОП. Очевидно, что этот сайт должен быть независимым от фармацевтических фирм.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Wed, 11 Jan 2012 23:55:45 +0400

число коечного фонда в США сократилось с 700 тысяч в 1960-м до 90 тысяч психиатрических коек в 2011 году. В ряду негативных последствий реформы увеличение количества бездомных больных

Это верно. Я никогда не видела такого количества бомжей с явными признаками… (все видели в больницах), как в Америке. В России столько их нет, очевидно, суровый климат, и они быстрее вымирают.

…и, что самое прискорбное, увеличение числа находящихся в тюрьмах страны психически больных лиц с подтвержденным диагнозом – до 400 тысяч человек на 2 млн заключенных.

Re: Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Wed, 11 Jan 2012 23:48:30 +0400

– Кризис отразился и на развитии психофармакологии. Как свидетельствует доклад исполкома Европейской коллегии нейропсихофармакологии (ECNP, 2011), нас ожидает вакуум в изучении новых лекарств в области нейронаук. Уже сейчас компания GlaxoSmithKline понижает уровень инвестиций в психиатрию, AstraZeneca исключает из своих исследовательских интересов шизофрению, биполярные расстройства, депрессии и тревогу. Не случайно, что за последние 10 лет в Европе лицензирован лишь один агомелатин (Вальдоксан®, Servier).

В стремлении к «сверхэтичности» компании зачастую «выбрасывают с водой и ребенка», т. е. создают препараты с минимумом побочных явлений и осложнений, но абсолютно неэффективные. Характерно в этой связи высказывание В. Л. Козловского в статье «Кризис психофармакологии, или Куда ведет нейрохимическая парадигма XX столетия» (2011).

Открытие генов вряд ли даст ключ к постановке точного диагноза в психиатрии

Wed, 11 Jan 2012 23:44:53 +0400

О современном состоянии психиатрии, о количестве больных в России и мире, о том, как связано число психиатрических больниц с числом тюремных заключенных и как в Японии называется шизофрения, «Газете.Ru» рассказывает профессор кафедры психиатрии ФУВ РНИМУ имени Н. И. Пирогова Петр Морозов.

– Действительно ли психиатрия как наука переживает серьезный кризис?

– В последние годы все чаще стали раздаваться голоса о системном кризисе в психиатрии. Этому вопросу посвящаются целые выпуски специализированных журналов, эту проблему делают основной на национальных конференциях. Что стоит за всем этим и в чем заключаются главные причины кризиса? Попытаюсь выделить главные причины ситуации, возникшей в нашей дисциплине в начале XXI века.
Итак, это прежде всего:
• разочарование вследствие отставания психиатрии как науки от других медицинских дисциплин;
• снижение престижа профессии;
• стигматизация;
• снижение общего клинического уровня, кризис образования, психологизация психиатрии;
• недостаточный уровень лечебной помощи;
• последствия социально-экономических изменений (глобализация, миграция населения, увеличение расходов без должного эффекта).